Free Trial

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.04 0.00 (-1.28%)
As of 08/15/2025 12:19 PM Eastern

VINC vs. PBLA, HEPA, ZVSA, BPTSY, VIRX, TRVN, MYMD, BON, CAPS, and NCNA

Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), ZyVersa Therapeutics (ZVSA), Biophytis (BPTSY), Viracta Therapeutics (VIRX), Trevena (TRVN), MyMD Pharmaceuticals (MYMD), Bon Natural Life (BON), Capstone Therapeutics (CAPS), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry.

Vincerx Pharma vs. Its Competitors

Panbela Therapeutics (NASDAQ:PBLA) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Panbela Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Panbela TherapeuticsN/A N/A -302.61%
Vincerx Pharma N/A -248.33%-132.73%

Panbela Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

Vincerx Pharma has a consensus target price of $40.00, indicating a potential upside of 103,259.17%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Panbela Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Panbela Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vincerx Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Panbela Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00
Vincerx PharmaN/AN/A-$40.16M-$20.600.00

In the previous week, Panbela Therapeutics had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Panbela Therapeutics and 0 mentions for Vincerx Pharma. Panbela Therapeutics' average media sentiment score of 1.00 beat Vincerx Pharma's score of 0.00 indicating that Panbela Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Panbela Therapeutics Positive
Vincerx Pharma Neutral

Summary

Vincerx Pharma beats Panbela Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VINC vs. The Competition

MetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$203K$851.84M$5.66B$9.82B
Dividend YieldN/A4.84%3.79%4.07%
P/E Ratio0.001.1930.5825.12
Price / SalesN/A26.45464.66115.60
Price / CashN/A19.5637.4059.05
Price / Book0.006.589.096.18
Net Income-$40.16M-$4.98M$3.25B$264.89M
7 Day PerformanceN/A2.96%7.32%4.18%
1 Month PerformanceN/A2.02%5.42%1.99%
1 Year PerformanceN/A13.30%30.66%24.22%

Vincerx Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
2.7277 of 5 stars
$0.04
-1.3%
$40.00
+103,259.2%
-99.7%$203KN/A0.0060Upcoming Earnings
PBLA
Panbela Therapeutics
1.1242 of 5 stars
$0.16
flat
N/A-57.3%$767KN/A0.006Short Interest ↓
HEPA
Hepion Pharmaceuticals
0.9261 of 5 stars
$0.06
-5.9%
N/A-99.8%$690KN/A-0.0120News Coverage
Short Interest ↓
Gap Down
ZVSA
ZyVersa Therapeutics
0.7198 of 5 stars
$0.14
-17.5%
N/A-94.9%$684KN/A0.002News Coverage
Gap Down
BPTSY
Biophytis
N/A$1.81
flat
N/A-67.2%$634KN/A0.0030Short Interest ↓
VIRX
Viracta Therapeutics
1.7702 of 5 stars
$0.01
flat
$1.75
+17,793.7%
N/A$389KN/A-0.0120
TRVN
Trevena
1.1514 of 5 stars
$0.26
+4.0%
$5.00
+1,823.1%
-92.6%$249K$443K-0.0140Short Interest ↑
MYMD
MyMD Pharmaceuticals
N/A$0.10
-1.6%
N/A-94.3%$229KN/A0.006High Trading Volume
BON
Bon Natural Life
N/A$1.30
-0.8%
N/AN/A$220K$23.84M0.00100Positive News
CAPS
Capstone Therapeutics
N/A$1.24
-6.1%
N/AN/A$210K$44.88M0.0038News Coverage
Earnings Report
NCNA
NuCana
3.5404 of 5 stars
$4.47
-30.6%
$5,000.00
+111,756.8%
-99.4%$200KN/A-0.6430Analyst Upgrade
Short Interest ↓
Gap Down

Related Companies and Tools


This page (NASDAQ:VINC) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners